Pfizer (PFE) and BioNTech (BNTX) provided an update on the Omicron variant. According to the companies, their preliminary laboratory studies demonstrated that the two doses of the Pfizer/BioNTech coronavirus vaccine show significantly reduced neutralization titers, and three doses neutralize the Omicron variant.
"Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it's clear from these preliminary data that protection is improved with a third dose of our vaccine," noted Albert Bourla, Chief Executive Officer (CEO) of Pfizer. "Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19."